Royalty Pharma plc has been showing a rally in its stock (NASDAQ:RPRX) despite ambiguous financial outlooks. Recently a buyout anticipation has been lowered as
Cytokinetics sold a share of its heart drug to
Royalty Pharma for up to $575 million. An increasing interest in
Royalty Pharma was evident with
Main Street Financial Solutions making a new $1.20 million investment in the company, among many others.
Royalty Pharma has also inked a $150 million royalty funding agreement with
Ascendis Pharma and reported a solid start of the year, beats Q2 earnings and revenue estimates, and raises 2024 outlook. However, scepticism among investors was noticeable as
Royalty Pharma insiders selling US$44m of shares. A bullish view on
Royalty Pharma was presented by
Goldman Sachs not only maintaining a 'buy' on its shares but also elevating price target. Despite recent volatility,
Royalty Pharma remains favoured by institutional owners who hold a whopping 70% of the company.
Royalty Pharma Stocks News Analytics from Sat, 08 Jul 2017 07:00:00 GMT to Fri, 13 Sep 2024 10:33:53 GMT -
Rating 6
- Innovation -3
- Information 9
- Rumor 4
